Earl K. Miller is Picower Professor of Neuroscience at the Massachusetts Institute of Technology, with faculty roles in the Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences. His lab focuses on neural mechanisms of cognition, especially working memory, attention and executive control, using both experimental and computational methods. He holds a B.A. from Kent State University and an M.A. and Ph.D. from Princeton University. In 2020, he received an honorary Doctor of Science degree from Kent State University.
Earl K. Miller
Professor of neuroscience
Massachusetts Institute of Technology
Selected articles
- “An integrative theory of prefrontal cortex function” | Annual Review of Neuroscience
- “Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices” | Science
- “The importance of mixed selectivity in complex cognitive tasks” | Nature
- “Gamma and beta bursts during working memory readout suggest roles in its volitional control” | Nature Communications
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.